Comment from Lotus Pharmaceutical Co., Ltd.

Summary: The commenter is seeking clarification on specific technical requirements within the draft guidance, particularly regarding drug substance information in DMFs and the handling of reference standards. They propose specific language to ensure that specifications for in-house reference materials are only provided where relevant to product quality.